Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now.
Roivant Sciences Ltd. (ROIV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | QVT Financial Daniel Gold | 26,387,021 | $572,598,356 | -11% | 49.1% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 10,677,894 | $231,710,300 | +48% | 0.35% |
| 3. | Two Seas Capital Sina Toussi | 9,791,891 | $212,484,035 | -17% | 4.38% |
| 4. | Rubric Capital Management David Rosen | 9,000,000 | $195,300,000 | -56% | 2.34% |
| 5. | Perceptive Advisors Joseph Edelman | 7,985,461 | $173,284,504 | +9% | 3.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.07 | 3,315 | $49,957.05 | 17,287,081 | 2025-09-18 | Filing | |
| $5.00 | 4,000,000 | $20,000,000.00 | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | $33,635.46 | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | $121,318.70 | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.51 | 587,390 | $16,159,098.90 | 13,736,547 | 2026-02-23 | Filing | |
| $27.15 | 1,012,610 | $27,492,361.50 | 13,736,547 | 2026-02-20 | Filing | |
| $27.42 | 1,400,000 | $38,388,000.00 | 13,736,547 | 2026-02-19 | Filing | |
| $26.49 | 200,000 | $5,298,000.00 | 1,654,597 | 2026-02-13 | Filing | |
| $26.50 | 225,000 | $5,962,500.00 | 15,127,329 | 2026-02-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 65,779,464 | $1,427,414,364 | 0.07% | |
| 2. | 58,359,553 | $1,266,402,346 | 0.08% | |
| 3. | 42,059,041 | $912,681,190 | 0.01% | |
| 4. | 41,170,475 | $893,399,288 | 0.02% | |
| 5. | 18,390,792 | $399,080,188 | 0.06% |
News See All
11 Most Promising Low-Cost Stocks to Buy Now
On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the state of equity markets, assessing which stocks are growing fast and trading cheaply.
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a bullish outlook on Roivant Sciences Ltd.
12 Best Healthcare Stocks Under $50 to Invest In
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Roivant Third Quarter 2025 Earnings Conference Call.
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress
Roivant saw its share prices jump by 19.4 percent week-on-week, hitting a new all-time high, as investors snapped up shares following encouraging results from its pipeline projects, with one already seeking...
Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline
Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now.
15 Best Stocks Under $25 to Buy Now
Stock futures were marginally lower early December 29, as traders grabbed profits at record index levels and exited prominent technology names and precious metals following an explosive rally.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Roivant's Second Quarter 2025 Earnings Call. [Operator Instructions] Please note that today's conference is being recorded.
Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center